ALB and cirrhosis of liver: Our results are in agreement with previous research, such as studies by Zhang et al. (2024) and Soy et al. (2006), which found that patients with lower ALB levels, such as those with liver cirrhosis, benefit more from adjusted TEIC dosing strategies.